title: Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox.
abstract: Myelodysplastic syndromes are characterized by ineffective hematopoiesis resulting in peripheral cytopenias. The majority of patients is dependent on regular transfusions of packed red blood cells leading to a secondary iron overload which might result in organ damage. Therefore, sufficient iron chelation therapy in selected patients is mandatory. Deferasirox (DFX) is an orally administered iron chelator which has been highly efficient in the treatment of secondary iron overload. Most frequent side effects of DFX are gastrointestinal disturbances, which leads in some patients to low adherence to the therapy. An expert panel met in Lisbon in July 2010 to develop recommendations on prevention and management of GI disturbances based on existing data and personal experiences.
authors: Department of Hematology and Oncology, University Hospital, Mannheim, Germany. florian.nolte@medma.uni-heidelberg.de
authors: Florian
authors: F
authors: Nolte
authors: Emanuele
authors: E
authors: Angelucci
authors: Photis
authors: P
authors: Beris
authors: Alan
authors: A
authors: Macwhannell
authors: Dominik
authors: D
authors: Selleslag
authors: Christiane
authors: C
authors: Schumann
authors: Blanca
authors: B
authors: Xicoy
authors: Antonio
authors: A
authors: Almeida
authors: Agnés
authors: A
authors: Guerci-Bresler
authors: Thamer
authors: T
authors: Sliwa
authors: Petra
authors: P
authors: Muus
authors: John
authors: J
authors: Porter
authors: Wolf-K
authors: WK
authors: Hofmann
mesh_terms: D001565:Benzoates / Q000009:adverse effects* / Q000627:therapeutic use*; D015913:Chelation Therapy / Q000009:adverse effects / Q000379:methods; D000077588:Deferasirox; D005767:Gastrointestinal Diseases / Q000139:chemically induced* / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects / Q000627:therapeutic use; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox